American Society of Hematology

The Hematologist: ASH News and Reports, the Society's member newsletter, is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

Meta-analysis of Bleeding Complications with Direct Oral Anticoagulants

Dr. David Garcia discusses advances in nonmalignant hematology.

Read more

Erythroferrone: A Missing Link in Iron Regulation

Dr. Mark Koury discusses the importance of erythroferrone.

Read more

Gene Therapy for Blood Disorders

Dr. Pamela Becker discusses advances in gene therapy for blood disorders.

Read more
View All

Presidents Column

Dr_ Linda Burns

Linda J. Burns, MD

Professor of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis
A Resounding Success: Inaugural Lymphoma Biology Meeting
October 22, 2014

Dr. Burns recaps the first lymphoma biology meeting.

View All

Clinical Trials Corner

Perioperative Management of Patients on the New Oral Anticoagulants
October 23, 2014

Dr. Garcia examines the usefulness of new oral anticoagulants.

View All

Ask The Hematologist

Ask the Hematologists: Anti-Phospholipid Antibodies and Pregnancy
July 1, 2014

Dr. Deepa Suryanarayan and Dr. David Garcia discuss their approach to a patient with laboratory evidence of anti-phospholipid antibodies who is pregnant or considering pregnancy.

View All

Mini Review

Progress in the Diagnosis and Management of Type 1 von Willebrand Disease
November 18, 2014

Drs. Jonathan Roberts, Robert Montgomery, and Gilbert C. White review recent progress in diagnosing and managing von Willebrand Disease.

View All

Op Ed

Is the NIH Expert Report on Sickle Cell Disease a “Clinical Practice Guideline We Can Trust?”
November 19, 2014

Dr. Alexis Thompson makes a thorough assessment of the latest clinical practice guidelines for sickle cell disease.

View All
  • ODAC Recommends Approval of First Biosimilar Drug

    The Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended the approval of the first application for a biosimilar drug on January 7.  The panel recommended that FDA approve the application for a biologic agent similar to filgrastim.  This drug would be used for a number of applications in hematology.

  • Medicare Begins Paying for Chronic Care Management

    On January 1, 2015, the Medicare program took a significant step towards recognizing that the role of a physician goes well beyond time in the exam room.  For the first time, Medicare will begin paying physicians for chronic care management.  ASH is pleased that Medicare is finally paying for this service, but still has concerns over the coding and billing requirements.  Read more to learn how this could affect hematology.

  • Highlights from the 2014 APP Lunch

    The ASH Practice Partnership (APP) hosted its annual luncheon event at the 2014 ASH Annual Meeting in San Francisco on Sunday, December 7. This year's topic was "Whither the Practice of Hematology in an Era of Mergers?" Read more to hear about the speakers and presentation.

  • SGR – Where Do We Go from Here?

    As the 113 th Congress winds down, it has become clear that this group of legislators will not be remembered as the one that permanently addressed the issues associated with Medicare physician payment.  Read more to find out what may happen with the SGR in 2015.

View all policy news
back to top